Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Tiantao Kuang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6894-4839; OpenAlex author ID A5010063636. Sources: OpenAlex.

Their work

Papers
34 (first author 5, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
67
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 4 papers · 2018: 3 papers · 2019: 6 papers · 2020: 3 papers · 2021: 4 papers · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 34

  1. microRNA-454 shows anti-angiogenic and anti-metastatic activity in pancreatic ductal adenocarcinoma by targeting LRP6 [Retraction]. Last author DOI 10.62347/jafg9813↗
  2. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13643↗
  3. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  4. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Co-author DOI 10.1007/s10620-022-07671-w↗
  5. Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. Co-author DOI 10.1080/15384101.2021.2014254↗
  6. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. First author DOI 10.21037/atm-22-1946↗
  7. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis. Co-author DOI 10.3389/fonc.2022.789351↗
  8. [Pancreas multidisciplinary team optimizes the diagnosis and treatment of pancreas-related diseases and improves the prognosis of pancreatic cancer patients]. Co-author DOI 10.3760/cma.j.cn112139-20220408-00149↗
  9. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.61498↗
  10. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Co-author DOI 10.1007/s10147-020-01782-y↗
  11. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… Co-author DOI 10.1038/s41419-021-04293-4↗
  12. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. Co-author DOI 10.1111/jcmm.16196↗
  13. Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancreatic Cancer Cells to Genistein. First author DOI 10.3389/fcell.2021.633035↗
  14. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection. Co-author DOI 10.1093/jjco/hyaa035↗
  15. HEATR1 Deficiency Promotes Chemoresistance via Upregulating ZNF185 and Downregulating SMAD4 in Pancreatic Cancer. Co-author DOI 10.1155/2020/3181596↗
  16. Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreatic Cancer. Last author DOI 10.1155/2020/6138039↗
  17. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. First author DOI 10.1007/s10238-018-00543-6↗
  18. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  19. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2019.111543↗
  20. Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo. First author DOI 10.1016/j.yexcr.2019.111605↗
  21. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s40880-019-0410-8↗
  22. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… Co-author DOI 10.7150/jca.35856↗
  23. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Co-author DOI 10.1080/15384101.2017.1405194↗
  24. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗
  25. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Co-author DOI 10.2217/fon-2017-0380↗
  26. SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. Co-author DOI 10.1177/1010428317695913↗
  27. Overexpression of miR-135b-5p promotes unfavorable clinical characteristics and poor prognosis via the repression of SFRP4 in pancreatic cancer. Last author DOI 10.18632/oncotarget.19150↗
  28. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. Co-author DOI 10.7150/jca.20917↗
  29. microRNA-454 shows anti-angiogenic and anti-metastatic activity in pancreatic ductal adenocarcinoma by targeting LRP6. Last author PMID 28123855↗
  30. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report. Co-author DOI 10.3892/ol.2014.2628↗
  31. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.1007/s12032-014-0260-9↗
  32. Optimization of MR diffusion-weighted imaging acquisitions for pancreatic cancer at 3.0T. First author DOI 10.1016/j.mri.2014.04.011↗
  33. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Co-author DOI 10.1007/s13277-013-0679-1↗
  34. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10238-011-0159-0↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dansong Wang · 23 shared papers, 2012–2024 · strength 2.36
  2. Wenchuan Wu · 18 shared papers, 2012–2024 · strength 1.81
  3. Yefei Rong · 17 shared papers, 2012–2024 · strength 1.74
  4. Xuefeng Xu · 15 shared papers, 2015–2024 · strength 1.68
  5. Wenhui Lou · 13 shared papers, 2014–2024 · strength 1.46
  6. Dayong Jin · 14 shared papers, 2012–2024 · strength 1.40
  7. Wenhui Lou · 9 shared papers, 2012–2024 · strength 0.77
  8. Jianang Li · 6 shared papers, 2017–2023 · strength 0.75
  9. Wenhui Lou · 5 shared papers, 2013–2023 · strength 0.62
  10. Ning Pu · 7 shared papers, 2017–2021 · strength 0.60
  11. Yaolin Xu · 4 shared papers, 2020–2024 · strength 0.58
  12. Xu Han · 5 shared papers, 2017–2021 · strength 0.54
  13. Weilin Mao · 3 shared papers, 2022–2023 · strength 0.53
  14. Yue Fan · 1 shared paper, 2026 · strength 0.43
  15. Yueming Zhang · 3 shared papers, 2020–2022 · strength 0.42
  16. Yue Fan · 3 shared papers, 2017–2021 · strength 0.42
  17. Yuan Fang · 4 shared papers, 2019–2020 · strength 0.42
  18. Lei Zhang · 3 shared papers, 2015–2022 · strength 0.40
  19. Hanlin Yin · 4 shared papers, 2018–2021 · strength 0.37
  20. Yuhong Zhou · 2 shared papers, 2024 · strength 0.33
  21. Tianyu Li · 2 shared papers, 2020–2021 · strength 0.32
  22. Jian-ang Li · 3 shared papers, 2018–2021 · strength 0.27
  23. Wentao Zhou · 3 shared papers, 2017–2019 · strength 0.25
  24. Lei Zhang · 1 shared paper, 2023 · strength 0.19
  25. Suizhi Gao · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.